Seeking to address a rising tide of retinal disease, Boehringer Ingelheim GmbH has agreed to pay Newton, Mass.-based Inflammasome Therapeutics Inc. as much as $160 million for rights to use its intravitreal drug delivery technology with up to three Boehringer compounds.